S
Simone U. Dalm
Researcher at Erasmus University Rotterdam
Publications - 29
Citations - 598
Simone U. Dalm is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Biodistribution & In vivo. The author has an hindex of 11, co-authored 23 publications receiving 375 citations. Previous affiliations of Simone U. Dalm include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
Simone U. Dalm,Julie Nonnekens,Gabriela N. Doeswijk,Erik de Blois,Dik C. van Gent,Mark Konijnenberg,Marion de Jong +6 more
TL;DR: The use of radiolabeled SSTR antagonists such as JR11 might enhance peptide receptor scintigraphy and peptide receptors radionuclide therapy of neuroendocrine tumors and provide successful imaging and therapeutic strategies for cancer types with relatively low SSTR expression.
Journal ArticleDOI
68Ga/177Lu-NeoBOMB1, A Novel Radiolabeled GRPR Antagonist For Theranostic Use In Oncology
Simone U. Dalm,Ingrid L. Bakker,Erik de Blois,Gabriela N. Doeswijk,Mark Konijnenberg,Francesca Orlandi,Donato Barbato,Mattia Tedesco,Theodosia Maina,Berthold A. Nock,Marion de Jong +10 more
TL;DR: The findings indicate that 68Ga- or 177Lu-labeled NeoBOMB1 is a promising radiotracer with excellent tumor uptake and favorable pharmacokinetics for imaging and therapy of GRPR-expressing tumors.
Journal ArticleDOI
In-vitro and in-vivo application of radiolabeled gastrin releasing peptide receptor ligands in breast cancer
Simone U. Dalm,John W.M. Martens,Anieta M. Sieuwerts,Carolien H.M. van Deurzen,Stuart Koelewijn,Erik de Blois,Theodosia Maina,Berthold A. Nock,Luc Brunel,Jean-Alain Fehrentz,Jean Martinez,Marion de Jong,Marleen Melis +12 more
TL;DR: Targeting GRP-R–expressing BC tumors using GRp-R radioligands is promising for nuclear imaging and therapy, especially in ER-positive BC patients.
Journal ArticleDOI
Therapeutic Applications of Pretargeting
TL;DR: An overview of the various targeted therapies in which pretargeting has been applied, discussing PRIT with alpha- and beta-emitters and as part of combination therapy, plus its use in drug delivery systems is given.
Journal ArticleDOI
Review: Receptor Targeted Nuclear Imaging of Breast Cancer.
TL;DR: An overview of the studies currently under investigation for receptor targeted nuclear imaging of breast cancer with main findings of imaging studies are summarized and (potential) purposes of lesion visualization by targeting these molecular markers are discussed.